Brief: Zydus Lifesciences Says Positive Topline Results From Completed Evidences-X Phase II(B) Clinical Trial Of Saroglitazar Mg
BRIEF-Zydus Lifesciences Says Positive Topline Results From Completed Evidences-X Phase II(B) Clinical Trial Of Saroglitazar Mg Aug 31 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - POSITIVE TOPLINE RESULTS FROM COMPLETED EVIDENCES-X PHASE II(B) CLINICAL TRIAL OF SAROGLITAZAR MG IN MASH
Source text: [ID:]
Further company coverage: ZYDU.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka